wega Breakfast
Agentic AI for Clinical Biomarkers in Research at Novartis
Date:
22 May 2025 from 08:30 to 10:00
Language:
English
Location:
St. Alban-Graben 3, Basel or remotely via Teams
Registration:
Agenda
08:15 - 08:30 a.m.
08:30 - 09:45 a.m.
09:45 - 10:00 a.m.
From 10:00 a.m.
Reception (for the participants on site)
Presentation
Q&A and discussion
Coffee, croissants and networking (for participants on site)
Abstract
Generative AI (GenAI) is reshaping pharmaceutical R&D, delivering faster insights and accelerating biomarker discovery. This talk outlines key GenAI achievements, introduces AI agents and their capabilities through published use cases, and highlights how Novartis is leveraging these tools in clinical biomarker research. We’ll also explore what’s next for agentic AI, with a look ahead to the breakthroughs expected between 2025 and 2030.
Our Speaker
Philippe MARC, PhD
Executive Director, Global Head of Integrated Data Sciences, Novartis Biomedical Research (BR)
At Novartis, my role is to maximize the impact of data on our research pipeline's speed and success rate. I work with the Biomedical Research Computational Science Council to develop a global data-driven strategy for R&D. Last few years, I have led the writing of our Biomedical Research Data Strategy, co-led the definition of our data42 Clinical platform, contributed to our Enterprise Data Management; and driven our Generative AI prototyping.
My team's primary focus is to shape and mine data to aid in the selection of the best compounds and companion biomarkers/diagnostics. We combine data from clinical and pre-clinical studies with multi-omics, digital devices, and imaging data, and apply Machine Learning/AI/GenAI techniques to those Data Products. Our goal is to design better drugs with fewer side effects using data-powered Translational Medicine.
Outside of Novartis, I serve as an advisor and lecturer, giving back to the educational community that has supported me.